通过CRISPR检测心脏瘤相关的microRNAs
Youlin Fu1, Peng Zhang1, Feng Chen1
1Department of Cardiology, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
Molecular biology reports
|January 11, 2025
概括
基于CRISPR的诊断 (CRISPR-Dx) 提供了一种有希望的分子方法,通过识别微RNA (miRNA) 失调来检测罕见的心脏瘤. 本综述探讨了CRISPR-Dx系统用于心脏瘤诊断和预后中的miRNA检测.
科学领域:
- 生物技术是生物技术.
- 分子诊断学 分子诊断
- 在瘤学瘤学.
背景情况:
- 心脏瘤很难仅仅通过成像来诊断.
- 微RNA (miRNA) 失调与心脏瘤,如心房肌瘤和血管肉瘤有关.
- 分子诊断为罕见的心脏瘤提供了替代检测方法.
研究的目的:
- 对微RNA (miRNA) 检测的基于CRISPR的诊断 (CRISPR-Dx) 进行批判性审查.
- 专注于CRISPR-Dx在诊断和确定心脏瘤的预后中的应用.
- 讨论CRISPR-Dx在这个领域的进展,挑战和未来方向.
主要方法:
- 通过Cas蛋白 (Cas9,Cas12,Cas13,Cas12f) 分类的多种CRISPR-Dx系统的概述.
- 讨论CRISPR/Cas系统与同热放大集成,用于低丰度miRNA检测.
- 包括无放大CRISPR-Dx系统用于直接检测miRNA.
主要成果:
- 克里斯普尔-Dx系统能够进行视觉读取,便携性和快速的多重miRNA检测.
- 已经开发了各种CRISPR-Dx平台,有和没有放大,用于miRNA分析.
- 突出了CRISPR-Dx在敏感和特定检测心脏瘤相关的miRNAs方面的潜力.
结论:
- CRISPR-Dx代表了罕见心脏瘤分子诊断的重大进展.
- 需要进一步的研究和开发来克服当前的陷,并优化CRISPR-Dx在心脏瘤学中的临床应用.
- 通过miRNA检测,CRISPR-Dx有望改善心脏瘤的诊断和预后.
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K


